F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the initiation of a Phase I clinical study of FG3622, the company’s lead antifungal drug candidate.Plenty of work to do yet before this is proven to be useful but this is another example of a growing list of new options becoming available to treat fungal infection.
The Phase 1 trial is a randomised, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of FG3622. 100 healthy volunteers will be enrolled in the trial which will evaluate single as well as multiple ascending doses of FG3622 which will be administered orally. This clinical trial is the first-in-human study in the global development of FG3622 and will be conducted in the UK.
FG3622 is the first of a new generation of novel class systemic antifungal agents active by both oral and intravenous administration to enter the clinic. The mechanism of action, discovered by scientists at F2G, involves the selective inhibition of a fungal enzyme and is completely distinct from any other class of marketed antifungal agent. The compound displays highly potent activity against a wide range of clinically significant moulds including the common pathogen Aspergillus fumigatus which is the leading cause of Invasive Aspergillosis, a serious, debilitating disease associated with very high mortality rates despite current therapy options.
Wednesday, 8 July 2009
First trial for new antifungal begins
It has been mentioned elsewhere in this blog that the search for new antifungals is important and ongoing. Particularly important are antifungals that have different modes of action when compared to existing antifungals so it is encouraging that a local company here in Manchester, UK have announced the first tests are under way of their new antifungal which has a novel target of activity: